Docetaxel first-line therapy in HER2-negative advanced breast cancer: a cohort study in patients with prospectively determined HER2 status

Anthony Gonçalves (1) , Mathilde Deblock (2) , Benjamin Esterni (3) , Carole Tarpin (3) , François Bertucci (4) , Marine Gilabert (5) , Emmanuelle Charafe-Jauffret (3) , Jocelyne Jacquemier (3) , Gilles Houvenaeghel (3) , Jean-Marc Extra (6) , Patrice Viens (5)

1 Département d’Oncologie Médicale [IPC, Marseille]
2 UHP - Université Henri Poincaré - Nancy 1
3 Institut Paoli-Calmettes
4 CRCM - Centre de Recherche en Cancérologie de Marseille
5 CRCM / U891 Inserm - Centre de Recherche en Cancérologie de Marseille
6 Département d'Oncologie Médicale

Domains: Life Sciences [q-bio]; Cancer

Anthony Gonçalves, Mathilde Deblock, Benjamin Esterni, Carole Tarpin, François Bertucci, et al.. Docetaxel first-line therapy in HER2-negative advanced breast cancer: a cohort study in patients with prospectively determined HER2 status. Anti-Cancer Drugs, 2009, 20 (10), pp.946-952. ⟨10.1097/cad.0b013e328331178f⟩. ⟨hal-03623811⟩